Two Trials of Intensive BP Lowering, Two Different Outcomes

Coverage from Medscape, STAT, Diabetes In Control, Medical Xpress, the limbic, EMJ, NeuroNews International, Medical Daily, and U.S. News & World Report describes two major trials of intensive blood pressure lowering that reached different conclusions. In one trial, intensive blood pressure control reduced cardiovascular events in stroke survivors, according to reporting from Medical Xpress, the limbic, EMJ, and NeuroNews International. U.S. News & World Report and Medical Xpress also covered a cheap drug that may prevent a second stroke by lowering blood pressure. In the other trial, reported by Diabetes In Control, Medical Xpress, and Medical Daily, a systolic target below 120 did not significantly cut heart events in 9,476 adults with type 2 diabetes. STAT framed the pair of studies as illustrating the challenges of lowering blood pressure after stroke or with diabetes, both in research and in practice.

The coverage emphasizes that the same strategy—pushing blood pressure lower than conventional targets—produced divergent outcomes depending on the patient population. Medical Xpress published separate stories on each trial, one headlined around cutting future cardiovascular risk after stroke or transient ischemic attack and the other stating that intensive blood pressure therapy did not cut cardiovascular events in adults with diabetes. Medical Daily specified the trial size of 9,476 adults with type 2 diabetes and the systolic target below 120. Diabetes In Control framed the diabetes trial as putting blood pressure targets to the test, asking whether the goal should be below 120 or below 140.

The background a reader needs is that blood pressure targets have long been debated in cardiology and diabetes care, with guidelines varying on how low systolic pressure should go. The stroke trial suggests benefit from more aggressive lowering in patients with prior cerebrovascular events, while the diabetes trial raises questions about whether the same intensity helps people with type 2 diabetes who have not had a stroke. The coverage does not yet specify the exact blood pressure numbers achieved in each arm, the duration of follow-up, or the specific drugs used beyond the mention of a cheap drug in the stroke prevention reporting.

What to watch next is whether clinical guidelines will diverge by condition, recommending lower targets for stroke survivors while maintaining more moderate targets for adults with type 2 diabetes. Coverage does not state when regulatory bodies or professional societies might review the data, nor whether the trials will be replicated in other populations. STAT’s framing suggests that translating these findings into practice will remain challenging, particularly because the two trials point in different directions despite testing a similar intervention.